ASH 2018 | PROMISE: MGUS/SMM screening study

Irene Ghobrial

Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the new PROMISE study (NCT03689595), aiming to determine the clinical and genomic alterations present in individuals with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) through screening those at high risk due to a family history or ethnicity. Dr Ghobrial, speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, shares the biggest myeloma screening study ever run to help prevent progression from occurring by catching the disease at an early stage.

Share this video